These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9461168)
21. Xenotransplantation--federal regulatory considerations. Bloom ET Curr Top Microbiol Immunol; 2003; 278():239-51. PubMed ID: 12934947 [TBL] [Abstract][Full Text] [Related]
22. Blood products part of FDA xenotransplant plan. Fox JL Nat Biotechnol; 2000 Mar; 18(3):258. PubMed ID: 10700130 [No Abstract] [Full Text] [Related]
23. Xenotransplantation trials 'should proceed but need guidelines'. Wadman M Nature; 1996 Jul; 382(6588):197. PubMed ID: 8717028 [No Abstract] [Full Text] [Related]
24. The US Public Health Service guideline for xenotransplantation: advances and limitations. Salomon DR Xenotransplantation; 2001 May; 8(2):86-9. PubMed ID: 11488261 [No Abstract] [Full Text] [Related]
25. American Society of Transplant Surgeons-American Society of Transplantation report of FDA meeting on regulatory expectations for xenotransplantation products. Adams A; Cendales LC; Cooper DKC; Cozzi E; Gill J; Judd E; Katz E; Kirk AD; Fishman JA; Reese PP; Wall A; Markmann JF Am J Transplant; 2023 Sep; 23(9):1290-1299. PubMed ID: 37217005 [TBL] [Abstract][Full Text] [Related]
26. Pig transplants 'should be banned. Brown P New Sci; 1997 Mar; 153(2071):6. PubMed ID: 11656630 [No Abstract] [Full Text] [Related]
28. Infectious disease control in relation to xenotransplantation in Korea. Park KS; Sung DY Xenotransplantation; 2006 Jul; 13(4):366-7. PubMed ID: 16768730 [No Abstract] [Full Text] [Related]
29. Xenotransplant risks to be aired at forum. Kaiser J Science; 1997 Feb; 275(5301):743. PubMed ID: 11644894 [No Abstract] [Full Text] [Related]
30. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316 [TBL] [Abstract][Full Text] [Related]
31. US Food and Drug Administration regulatory approaches for xenotransplantation products and xenografts. Arcidiacono J Xenotransplantation; 2020 Nov; 27(6):e12626. PubMed ID: 32776377 [TBL] [Abstract][Full Text] [Related]
32. FDA turns down moratorium demand on xenotransplants. Wadman M Nature; 1998 Jan; 391(6666):423. PubMed ID: 9461202 [No Abstract] [Full Text] [Related]
33. Xenotransplantation at the crossroads. Pierson RN Xenotransplantation; 2004 Sep; 11(5):391-3. PubMed ID: 15303974 [No Abstract] [Full Text] [Related]
34. FDA finalizing policy statement on industry-supported activities. Am J Hosp Pharm; 1993 Mar; 50(3):391. PubMed ID: 8442443 [No Abstract] [Full Text] [Related]
35. Xenotransplantation at a crossroads: prevention versus progress. Allan JS Nat Med; 1996 Jan; 2(1):18-21. PubMed ID: 8564824 [TBL] [Abstract][Full Text] [Related]
37. They are from the government and they really are here to help you. Woosley RL J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889 [No Abstract] [Full Text] [Related]
38. A shrewd and ethical approach to xenotransplantation. Bach FH; Ivinson AJ Trends Biotechnol; 2002 Mar; 20(3):129-31. PubMed ID: 11841865 [TBL] [Abstract][Full Text] [Related]
39. FDA wants more disclosure of gene-therapy and xenotransplantation risks. McCarthy M Lancet; 2001 Jan; 357(9252):292. PubMed ID: 11214142 [No Abstract] [Full Text] [Related]
40. FDA and drug approval. Faich GA J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):24S. PubMed ID: 8770838 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]